| Vol. 9.36 – 17 September, 2020 |
| |
|
|
| Scientists showed that while AXL-low expressing epidermal growth factor receptor mutated lung cancer (EGFRmut-LC) cells were more sensitive to osimertinib than AXL-high expressing EGFRmut-LC cells, a small population emerged osimertinib tolerant. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers report that GSK3008348 bound to αvβ6 with high affinity in human idiopathic pulmonary fibrosis lung and reduced downstream pro-fibrotic transforming growth factor-β signaling to normal levels. In human lung epithelial cells, GSK3008348 induced rapid internalization and lysosomal degradation of the αvβ6 integrin. [Nature Communications] |
|
|
|
| The authors collected nasal cells by brushing to determine ionocyte abundance. Nasal and bronchial cells were also expanded in vitro and reprogrammed to differentiated epithelia for morphological and functional studies. [Cells] |
|
|
|
| Scientists identified the critical differential expression miRNAs that regulated the pathological response in RSV‐infected airway epithelial cells. [Journal of Cellular and Molecular Medicine] |
|
|
|
| Researchers investigated the roles of TRPA1 and TRPV3 in regulating endoplasmic reticulum stress and cytotoxicity in human bronchial epithelial cells treated with pneumotoxic wood smoke particulate matter and chemical agonists of each channel. [Molecular Pharmacology] |
| |
|
|
| Scientists showed that TP53 loss initiated a pharmacologically actionable secretory process that drove lung adenocarcinoma progression. [Journal of Clinical Investigation] |
|
|
|
| Concomitant CDK4 inactivation and RAF1 ablation prevented tumor progression and induced complete regression in 25% of KRAS/p53-driven advanced lung tumors, yet a significant percentage of those tumors that underwent partial regression retained a population of CDK4/RAF1-resistant cells. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers identified a group of Y chromosome-expressed long non-coding RNA that were involved in male NSCLC radiation sensitivity. [Cancer Research] |
|
|
|
| Scientists confirmed that DNA damage-regulated autophagy modulator 1 (DRAM1) inhibited the growth, migration, and invasion of NSCLC cells in vitro. [Cell Death & Disease] |
|
|
|
| Researchers found that ectopic expression of metallothionein 1D pseudogene (MT1DP) sensitized A549 and H1299 cells to erastin-induced ferroptosis through downregulation of nuclear factor erythroid 2-related factor 2 (NRF2); in addition, ectopic MT1DP upregulated malondialdehyde and reactive oxygen species levels, increased intracellular ferrous iron concentration, and reduced glutathione levels in cancer cells exposed to erastin, whereas downregulation of MT1DP showed the opposite effect. [Cell Death & Disease] |
|
|
|
| The authors clarified whether heat shock protein B8 could bring benefits to proliferation and migration of lung adenocarcinoma and its underlying mechanisms. [Molecular and Cellular Biology] |
|
|
|
| Scientists investigated the effect of cellular retinol binding protein-1 (CRBP-1) transfection in the H460 human NSCLC cell line, normally not expressing CRBP-1. [Molecular Biology Reports] |
|
|
|
|
| The authors examine the role of the extracellular matrix and its associated factors in establishing a fertile soil from which individual tumor cells and micrometastases establish primary and secondary tumors. They focus on the role of the lung extracellular matrix in providing the architectural support for local metastases in lung cancer, and distant metastases in many solid tumors. [Frontiers in Oncology] |
|
|
|
|
| Moderna, Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for the treatment of cystic fibrosis. [Moderna, Inc.] |
|
|
|
| Halozyme Therapeutics, Inc. announced that its collaborator, Roche, presented a poster with data from Part 1 of its Phase Ib study evaluating atezolizumab for subcutaneous administration utilizing Halozyme’s ENHANZE® technology in patients with locally advanced or metastatic NSCLC. [Halozyme Therapeutics, Inc.] |
|
|
|
|
|
|
|
| Old Dominion University – Norfolk, Virginia, United States |
|
|
|
| Justus-Liebig-Universität Gießen – Gießen, Germany |
|
|
|
| NYU Langone Health – New York, New York, United States |
|
|
|
| Institut Mondor de Recherche Biomédicale (IMRB) – Creteil, France |
|
|
|
| National Heart and Lung Institute – London, United Kingdom |
|
|
|
|